On this page
What it is
A long-acting analogue of glucagon-like peptide-1 (GLP-1), an incretin hormone released from the gut after eating. Structural modifications extend its half-life so it can be dosed weekly rather than continuously.
How it is proposed to work
Agonism at the GLP-1 receptor enhances glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and acts on hypothalamic circuits involved in appetite regulation.
Approved medical uses
Type 2 diabetes and chronic weight management, with jurisdiction-specific labelling. Cardiovascular risk-reduction claims exist in some labels and not others. Always read the label for the specific product and country.
Human research
Each entry states what the study found and, separately, what it cannot show.
- Systematic review2023n = 14,940
Systematic review and meta-analysis of randomised trials of subcutaneous semaglutide in type 2 diabetes
Finding. Pooling 17 randomised trials enrolling 14,940 adults with type 2 diabetes, subcutaneous semaglutide lowered HbA1c against placebo, with mean differences of 0.97% and 1.36% at the two doses analysed. In a separate set of comparisons against other glucose-lowering agents rather than placebo, it lowered HbA1c by 0.56% and 0.63% at those same two doses; body weight reduction and blood pressure control also favoured semaglutide. Nausea, diarrhoea and vomiting were more common on semaglutide. The pooled data did not detect an increase in adverse events overall, serious adverse events, severe or blood-glucose-confirmed hypoglycaemia, acute pancreatitis or diabetic retinopathy against either placebo or active comparators, though no detected increase across trials of this size and duration is not the same as established absence of harm.
Limitation. Heterogeneity in the two HbA1c-versus-placebo poolings was high (I2 of 91% and 84%), and the authors attribute it mainly to the different antidiabetic agents used as controls, alongside differences in race, treatment duration and background medication. They further note that two of the included trials recruited only in Japan, that all of the included studies were funded by the manufacturer so commercial sponsorship may raise bias risk, and that publication bias cannot be ruled out when only published data are pooled. Trial populations are selected, so effect sizes in unselected real-world use are typically smaller, and the authors state that further large, multicentre randomised trials are still needed for more robust evidence.
- Randomised controlled trial2023n = 17,604
Cardiovascular outcomes in overweight or obesity without diabetes
Finding. In patients aged 45 or older with preexisting cardiovascular disease and a body-mass index of 27 or greater but no history of diabetes, a primary composite event — death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke — occurred in 6.5% of the once-weekly subcutaneous semaglutide group versus 8.0% on placebo (hazard ratio 0.80; 95% CI 0.72 to 0.90; P<0.001), over a mean follow-up of 39.8 months in this multicentre, double-blind, randomised, placebo-controlled, event-driven superiority trial.
Limitation. Adverse events leading to permanent discontinuation of the trial product occurred in 16.6% of the semaglutide group and 8.2% of the placebo group (P<0.001). The trial was funded by Novo Nordisk, the manufacturer of the drug. Enrolment was restricted to people aged 45 or older who already had cardiovascular disease, were overweight or obese, and had no history of diabetes, so the result speaks to that population and to the single weekly subcutaneous dose level tested; it does not transfer automatically to healthy people using the drug for cosmetic weight loss.
Preclinical research
Animal and laboratory work. Useful for generating hypotheses; it cannot establish that something works in people.
No preclinical studies catalogued.
Potential safety concerns
- CautionEstablished
Gastrointestinal adverse effects are common and are the leading cause of discontinuation. Rare but serious events including pancreatitis appear in labelling.
- CautionPromising
Loss of lean mass alongside fat mass is observed. Its long-term functional significance is an active research question.
- SeriousEstablished
Compounded and grey-market 'semaglutide' products have been associated with dosing errors and adverse events. Regulators in several jurisdictions have issued warnings.
Known interactions and contraindication considerations
- Delayed gastric emptying can alter absorption of concomitant oral medicines.
- Combination with insulin or sulfonylureas raises hypoglycaemia risk and generally requires dose review by a prescriber.
- Contraindication considerations exist around personal or family history of medullary thyroid carcinoma and MEN 2 in several labels.
This list is not exhaustive and is not a substitute for a clinician reviewing your full medication history.
Regulatory status
Status is shown per jurisdiction and is accurate only as of the date stated. Where a compound is approved, the approval is bound to a specific formulation, manufacturer and indication — shown in the detail column.
| Jurisdiction | Standing | Detail |
|---|---|---|
United States FDA | Approved as of 15 Jan 2026 |
Approval is indication-specific and formulation-specific. Compounded semaglutide is not an approved product. |
European Union EMA | Approved as of 15 Jan 2026 |
Centrally authorised. Indication wording differs from the US label. |
India CDSCO | Approved as of 15 Jan 2026 |
Prescription-only. Availability and approved indications differ from the US and EU. Verify current CDSCO status before relying on this. |
How it is being used
What the grey community actually runs, the reasoning they give, and our read on whether it follows from known biology. This is observation, not evidence, and not a recommendation.
Weight management and metabolic maintenance
What is run
Two distinct patterns. The first follows the labelled titration toward a target weight. The second deliberately stays below the labelled range indefinitely, framed as metabolic maintenance rather than treatment.
Their mechanistic reasoning
That GLP-1 receptor agonism regulates appetite centrally and improves glycaemia, and that a lower exposure retains a proportionate share of that benefit with fewer gastrointestinal effects.
Reported in the community’s own terms. Not our position.
Stacked with
- Resistance training and a protein target—The pairing with real evidence behind it. Protects the lean mass that the therapy otherwise costs.
- Cagrilintide or other amylin analogues—Separate satiety pathway, expected to be additive rather than redundant.
- GH secretagogues, in recomposition protocols—Intended to offset lean-mass loss. The appetite stimulation works directly against the incretin.
Regimen shape
- Dose
- figure withheld
- Scale
- Labelled range, or deliberately below it
- Route
- Subcutaneous injection
- Frequency
- Weekly
- Timing
- Fixed day, no meal relationship required
- Duration
- Continuous; maintenance patterns often indefinite
Our read
Dose-dependence is real, so a smaller exposure producing a smaller effect is sound. The longevity framing is where it overreaches — outcome data comes from specific populations at studied doses and establishes nothing about a metabolically healthy person at an unstudied exposure. The practice borrows credibility from trials it is not running.
What the community reports
The comparison is between how sure the community is and how much is actually known — evidence strength, not direction. A compound can have solid research that came out negative.
The most enthusiastic discourse in this entire library, and — unusually — largely justified for the approved use. The problem is drift: enthusiasm earned by trial evidence in treatment gets transferred wholesale to indefinite low-dose use in healthy people, which no trial has examined.
Commonly reported as helping
- Substantial appetite reduction, frequently described as the first time hunger felt manageable
- Reduced intrusive thoughts about food, reported so consistently that the community has its own name for it
- Weight loss reported as easier than any previous attempt
- Incidental reports of reduced alcohol intake and other appetitive behaviours
Also reported, when it goes wrong
- Nausea, constipation and reflux, the leading reasons for stopping
- Fatigue and reduced training capacity during rapid loss
- Visible loss of muscle and facial volume
- Rapid regain after stopping, reported consistently and often with distress
Why these reports can mislead
The core effect is real and well evidenced, so scepticism about *whether it works* is misplaced. The reporting bias is about duration: forums are full of month-three posts and comparatively empty of year-three posts. People who regained the weight tend to leave the community rather than update it.
Direct quotations are not published here yet. We will only carry verbatim reports once they are sourced, dated and checked — an unattributed quote is a testimonial, and testimonials are exactly what this section exists to replace.
Watch for, in this use specifically
- Compounded and grey-market product is where the documented harm concentrates — concentration error, not the molecule.
- Delayed gastric emptying alters absorption of oral medicines with narrow therapeutic windows.
- Have a plan for stopping before you start. Regain after discontinuation is consistent and substantial.
Active clinical trials
- NCT00000001Phase 3Active, not recruitingn = 17,604
Long-term cardiometabolic outcomes with GLP-1 receptor agonism
Obesity with established cardiovascular disease · United States, Germany, India · updated 12 Jun 2026
What remains unknown
The questions that would change our assessment if they were answered.
- What happens to weight, lean mass and cardiometabolic risk after discontinuation, over years rather than months?
- How much of the cardiovascular benefit is independent of weight loss?
- What are the long-term effects in people without diabetes or established cardiovascular disease?
References
- 1.Hu S, Su X, Fan G. Efficacy and tolerability of the subcutaneous semaglutide for type 2 diabetes patients: an updated systematic review and meta-analysis. Diabetol Metab Syndr. 2023;15(1):218.PMID 37891683doi
- 2.Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389(24):2221-2232.PMID 37952131doi
Editorial change history
When we change a grade or a regulatory note, we log it here rather than editing quietly.
Scheduled review. Regulatory table re-checked; no change to standings.
Added lean-mass safety signal and reclassified it from watch to caution.
Spotted something wrong? Tell us — we publish corrections.